Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Short term blood pressure alterations in recently COVID-19 vaccinated patients

**ARTICLE INFO**

**Keywords**
COVID-19 vaccination
Hypertension
Blood pressure

**Dear Editor,**

The global medical community supports that vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is crucial for reaching the herd immunity threshold needed to curb the pandemic and return to normal life. Till now, a rapid development of the efficacy and safety of COVID-19 vaccines have been tested in randomised clinical trials [1–3], some concerns have been raised based on very limited data regarding a non-immediate hypertensive response post vaccination. Mild to moderate elevated arterial blood pressure (BP) levels have been documented a few days after a single or two-doses vaccine [4,5]. The present study sought to investigate this observation in patients with known hypertension (HTN) and healthy controls.

A total of 100 patients between the age of 50 to 70 years old were studied. They were randomly assigned to one of the approved and available vaccines (Pfizer, Astra Zeneca, Moderna or Johnson & Johnson). Half of them were hypertensives under medical treatment and half of them were not. All participants had systolic BP ≥140 mmHg and diastolic BP <90 mmHg before vaccination and volunteered for standard daily home BP measurements (HBPM) and ambulatory BP measurements (ABPM) between the 5th and the 20th day after considered fully COVID-19 vaccinated.

Taking under consideration the BP recordings, all patients, hypertensives or not, had at some point a recorded hypertensive response defined as systolic BP values ≥140 mmHg and/or diastolic BP values ≥90 mmHg between day 5 and day 20 post vaccination irrespective of vaccine type. Hypertensives were older and with higher body mass index. Five of 50 hypertensive patients received additional medication whereas some of the non-hypertensive patients started life modification changes and systematic BP measurements for a possible diagnosis of HTN (Table 1).

These preliminary results were in accordance with two recently published studies that included patients receiving a messenger RNA (mRNA) based vaccine against COVID-19. The first one was a prospective survey of 113 health workers with apparently normal home BP vaccinated with Pfizer from Italy. Among them, six participants (5.3%) reported a rise in the average self-measured home systolic or diastolic BP by at least 10 mmHg within the first five days following the first dose of vaccine. Four subjects required modification of antihypertensive treatment and two patients experienced a BP rise after the second dose as well. Notably, previous exposure to SARS-CoV-2 was correlated with a higher probability of a BP rise post vaccination [4]. The second one was a case series of nine patients with previous well controlled HTN conducted in a vaccination centre in Lausanne in Switzerland. Systolic and diastolic BP increased above the values of 180 mmHg and 110 mmHg, respectively, within minutes following vaccination with Pfizer or Moderna [5].

The potential pathophysiologic link between COVID-19 vaccination and BP rise remains unclear. Regarding the mRNA-based vaccines it has been noted that mRNA encodes the Spike protein of SARS-CoV-2 in the cells reached by the vaccine. In turn, the Spike proteins congregate into the cytoplasm and migrate to the cell surface to protrude with a native-like conformation and be recognized by the immune system. Moreover, the Spike proteins circulate in the blood as free-floating proteins after cells being destroyed and interact with the angiotensin-converting enzyme 2 (ACE2) receptors resulting in the internalization and the degradation of the receptors. The loss of ACE2 receptors activity and the inactivation of angiotensin II decrease the production of angiotensin 1–7. The subsequent imbalance between angiotensin II (overactivity) and angiotensin1–7 (deficiency) might have a role in the pathogenesis of HTN after COVID-19 vaccination. An alternative explanation could be a potential hypertensive response to the ingredients of the vaccines including polyethylenglycol or tromethamine. Last but not least, emotional factors, stress, pain response, the white coat effect or even undiagnosed HTN might be hypothesized as triggers of this reaction in vaccinated subjects [6].

It is well known that SARS-CoV-2 interacts with ACE2 in order to enter the host’s cells including cardiac myocytes and alveolar epithelial cells. Initial reports suggested that HTN might be involved in the pathogenesis of COVID-19 and should be considered as a clinical predictor of disease severity in infected patients. A pooled analysis of 13 studies from China pointed out that HTN was correlated with a nearly 2.5-fold higher risk for severe or fatal COVID-19, particularly in the elderly [7]. Therefore, it was recommended patients with cardiac diseases treated with ACE inhibitors or angiotensin II receptor blockers (ARBs) to be close monitored. Contrary to this hypothesis, the European Society of Cardiology (ESC) supports the unstoppable use of renin-angiotensin system (RAS) inhibitors in hypertensive patients with COVID-19 that are already on these drugs due to the substantial better survival compared to those not on these drugs [8].

https://doi.org/10.1016/j.ejim.2021.11.017
Received 12 October 2021; Received in revised form 14 November 2021; Accepted 25 November 2021
Available online 29 November 2021
0953-6205/© 2021 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
Several side effects that have been reported after COVID-19 vaccination include haematological and vascular events, myocarditis, pericarditis or hyperglycaemia in short time intervals after the first or second dose. However, the frequency is unclear and the exact pathophysiological mechanisms are still inconclusive. Of note, the risks of these adverse events are significantly lower compared to those correlated with SARS-CoV-2 infection [9,10]. The present study implies a potential effect of COVID-19 vaccination on BP rather than a new side effect.

To conclude, vaccination for COVID-19 seems to be related with a short period of hypertensive response. This phenomenon was partial and mostly observed in older overweight hypertensives. Probably, BP should be systematically measured at home at least a week prior and after vaccination. However, the overall benefits of COVID-19 vaccination outweigh the risk of these observations.

References

[1] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetsuriani N, Segall N, Solis J, Broz A, Fiero C, Schwartz H, Neuzil K, Corey L, Gilbert P, Jans H, Pollmann D, Marovich M, Mascola J, Polakowski I, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T, Group CS. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403-16.

[2] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Perez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, French Jr RW, Hammitt LL, Tureci O, Nell H, Schafer A, Ural S, Trennan DB, Mather S, Dormitzer PR, Sahin U, Jansen KU, Gruber WC, Group CCT. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020;383:2603-15.

[3] Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Oxford CTG: safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397:99-111.

[4] Zappa M, Verdeccia P, Spanevello A, Visca D, Angeli F. Blood pressure increase after Pfizer/BioNTech SARS-CoV-2 vaccine. Eur J Intern Med 2021;90:111-3.

[5] Meylan S, Livio F, Foerster M, Genoud PJ, Marguet F, Wuerzner G, et al. Stage III hypertension in patients after mRNA-based SARS-CoV-2 vaccination. Hypertension 2021;77. e56-e7.

[6] Angeli F, Spanevello A, Reboldi G, Visca D, Verdeccia P. SARS-CoV-2 vaccines: lights and shadows. Eur J Intern Med 2021;88:1-8.

[7] Lippi G, Wong J, Henry BM. Hypertension in patients with coronavirus disease 2019 (COVID-19); a pooled analysis. Pol Arch Intern Med 2020;130:304-9.

[8] Cardiology Eso: ESC guidance for the diagnosis and management of CV disease during the COVID-19 pandemic.

[9] Hippisley-Cox J, Patone M, Mei XW, Saatci D, Dixon S, Khunti K, Zaccardi F, Watkins P, Shankar-Hari M, Dodge J, Harrison DA, Griffin SJ, Sherlock A, Coupland CAC. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ 2021;374:n1931.

[10] Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson IV, Robicsek A. Myocarditis and pericarditis after vaccination for COVID-19. JAMA 2021.

Elias Sanidas1, Theoharis Anastasiou1, Dimitrios Papadopoulos2, Maria Velliou1*, Marina Mantzourani2
1 Hypertension Excellence Centre – ESH, LAIKO General Hospital, Athens, Greece
2 1st Dept. of Internal Medicine, LAIKO General Hospital, University of Athens, Medical School, Athens, Greece

* Corresponding author at: Hypertension Excellence Centre – ESH, LAIKO General Hospital, 17 Agiou Thoma Street, 11527, Athens, Greece.

E-mail address: maravelliou84@yahoo.gr (M. Velliou).